EICHOR
● Recruiting
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma (HCC) · Sponsor: VA Office of Research and Development
About this study
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
This description comes directly from the study's public registry record.
Talk to the study team
Binu V John, MD MPH · (305) 575-7000 · binu.john@va.gov
Flavia R Carneiro, PhD · (305) 575-7762 · flavia.carneiro@va.gov
Always discuss trial participation with your own doctor first.
Locations (2)
| VA Greater Los Angeles Healthcare System, West Los Angeles, CA | West Los Angeles, California, United States | Recruiting |
| Miami VA Healthcare System, Miami, FL | Miami, Florida, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.